

# Investigating the Anxiolytic Potential of Novel Plant Extract Combinations in Rats: A Comparative Toxicological Analysis

Georgi Nikolov, Anastasios Georgiev, Ivan Angelov, Radoslava Dimitrova, Kalin Kostov, Dimitrinka Peneva, Milena Stefanova, Ivan Hadjiev

University of Plovdiv "Paisii Hilendarski", Bulgaria, Department of Pharmacology and Clinical Pharmacology, Faculty of Pharmacy;

## ABSTRACT

Anxiety is a significant social problem that could deteriorate the quality of life of individuals. It disturbs the normal circadian rhythms, leading to an increase of cardio-vascular diseases and distortions in the functions of the immune system. Antistress I and Antistress II are herbal combinations containing in different proportions dry extracts obtained from *Serratula coronata*, *Hypericum perforatum*, *Valeriana officinalis*, *Crataegus monogyna* and *Melissa officinalis*. The present study evaluates the acute toxicity and the anxiolytic effect of these combinations and the individual extracts which they contain after their oral administration to male Wistar rats. Doses of 5g/kg b.w. and 10g/kg b.w. are used for the evaluation of acute toxicity. Assessment of the anxiolytic effect is carried out at three doses – 100, 250 and 500 mg/kg b.w. by using the test - Elevated plus maze. The results about the acute toxicity show a survival rate of 100% for all extracts at a dose up to 10g/kg b.w. The evaluation of the anxiolytic effect on an acute stress model in rats demonstrates that both combinations Antistress I and Antistress II possess anxiolytic properties which are significant only at the highest dose. The results also give us the reason to conclude that the effect of Antistress II on anxiety is better compared to Antistress I.

**Keywords:** Elevated plus maze, rats, combinations of plant extracts, *Serratula coronata*, *Hypericum perforatum*, *Valeriana officinalis*, *Crataegus monogyna*, *Melissa officinalis*.

## INTRODUCTION

Half of the global pharmaceutical market is occupied by plant-based therapy and drugs<sup>1</sup>. Plant products used for therapeutic and prophylactic purposes, have an easy and convenient method of use that provides better compliance of patients in the prevention and treatment of various diseases. Natural products possess unique chemical formulas that are the base for the creation of new drugs. 25% of all medicines originate from plant source and they could be included in new combinations<sup>2</sup>. Combining plant extracts leads to different mechanisms of action and influences various aspects in the pathogenesis of stress, which is risk factor for socially significant diseases such as anxiety<sup>3</sup>, depression<sup>4,5</sup>, hypertension<sup>3</sup>, diabetes<sup>6</sup>, allergic reactions<sup>7</sup>, autoimmune diseases<sup>8</sup> and infections<sup>9</sup>. The purpose of the present experimental study is to assess the anxiolytic effect of two combined plant extracts Antistress I and Antistress II after the application of acute stress model to rats. The combinations contain in different proportions individual plant extracts obtained from *Serratula coronata*, *Hypericum perforatum*, *Valeriana officinalis*, *Crataegus monogyna* and *Melissa officinalis*.

## MATERIALS AND METHODS

"Antistress I" is a combination containing dry extracts from *Valeriana officinalis*, *Melissa officinalis*, *Crataegus monogyna* and *Serratula coronata* in a ratio of 4: 3: 3: 1. "Antistress II" contains *Valeriana officinalis*, *Hypericum perforatum* and *Serratula coronata* in a ratio of 4,5: 4,5: 1. The chemical identification of the extracts is carried out at the Department of Chemistry and Biochemistry, Faculty of Pharmacy, Medical university of Plovdiv by using Highperformance liquid chromatography (HPLC). Each

extract is standardized on the base of the following substances: *Valeriana officinalis* – valerenic acid and bornyl acetate; *Melissa officinalis* – rosmarinic acid and caffeic acid; *Crataegus monogyna* – rutin, quercetin and hyperoside; *Serratula coronata* – 20-hydroxyecdysone and quercetin, *Hypericum perforatum* – hypericin.

The experiments with laboratory animals are conducted at the Department of Pharmacology and clinical pharmacology, Faculty of Medicine, Medical university of Plovdiv in order to evaluate the acute toxicity and the anxiolytic effect of the two combinations and the individual dry extracts which they contain. 250 male Wistar rats weighting 180-200g are used in these experiments. (160 animals for studying the anxiolytic effect and 90 animals for studying the acute toxicity). The use of animals is authorized by the Bulgarian food safety agency (Permit № 127 from 09.12.2015) and approved by the ethical commission at the Medical university of Plovdiv (protocol №3 from 21.04.2016). This experiment is part of university project HO-10/2015.

*A. Design of the experiment used for evaluation of acute toxicity.*

Experimental animals (90 in total) are divided into 15 groups of 6 animals in each group. Table 1 shows the design of the experiment used to evaluate the acute toxicity of combinations Antistress I and II and the individual plant extracts included in these combinations. The animals are treated with the extracts orally by using a gavage. The survival rate is reported 24 hours after the administration of the extracts.

*B. Design of the experiment used for evaluation of anxiolytic effect of combinations and individual plant*

extracts in different doses after applying an acute stress model to rats.

160 male Wistar rats are divided into 23 groups. For 14 days, the animals from different groups are treated daily by using a gavage at doses of 100, 250 and 500 mg / kg b.w. with two combinations and five individual plant extracts, contained in them. Table 2 shows the design of the experiment used for the evaluation of the anxiolytic effect in model of acute stress of the two combinations - Antistress I and Antistress II and the individual extracts included in them.

On the 15<sup>th</sup> day of the experiment one hour after the oral treatment, all animals (excluding these without stress – group C<sub>0</sub>) are put in refrigerator at 5°C for one hour (model of acute cold stress). The anxiolytic effect is evaluated by using the test – Elevated plus maze. The following indicators are measured: 1. Time spent in opened arms (Totk) (s), 2. Number of entries in opened arms (Notk), 3. Total number of entries in both arms (Ntot), 4. Ratio of opened/total arm entries (Notn). Criteria for anxiolytic effect are: increase of Totk, Notk and Notn. Criterion for sedative effect is decrease of Ntot.

#### Statistics

Statistical assessment of the results is made with IBM SPSS 17.0. Normality of distribution is determined by using Shapiro-Wilk test. Arithmetic mean and SEM are identified for each indicator. Comparison of the results between groups is done by using the Independent Sample T test for normal distribution or Mann-Whitney U test when the distribution is not normal. P value < 0,05 is considered statistically significant.

## RESULTS

In the study of acute toxicity, all animals survive 24 hours after the oral administration of the combinations and the individual extracts at dose up to 10g/kg b.w thus the survival rate is 100%. Moreover the usage of such high doses in this experiment leads us to the conclusion that the tested extracts are practically non-toxic. Referring to the available literature data, the usual doses of the individual extracts range from 100 mg/kg b.w. to 500mg/kg b.w. The following results are observed by studying the anxiolytic effect of the extracts at doses of 100, 250 and 500 mg/kg b.w. using a model of acute stress:

Results of the evaluated combinations and individual extracts at doses of 100, 250 and 500 mg/kg b.w. compared to the results of the control group after applying a model of acute stress Table 3 compares the time spent in the opened arms of Elevated plus maze measured in seconds - Totk (s) after Antistress I, Antistress II and the individual extracts contained in them are administrated on male Wistar rats for 14 days.

The comparison between the two control groups shows that in group C<sub>0</sub> there is a significant increase of Totk compared to group C. This proves that the test - Elevated plus maze is appropriate for evaluation of behavioral changes in rats exposed to acute stress model. Except in C<sub>0</sub> there is an increase of Totk in groups AS1<sub>250</sub>, AS1<sub>500</sub>, AS2<sub>100</sub>, AS2<sub>500</sub>, SER<sub>100</sub>, SER<sub>500</sub>, VAL<sub>100</sub>, VAL<sub>500</sub>, CRA<sub>100</sub>, CRA<sub>500</sub>, MEL<sub>250</sub>, MEL<sub>500</sub> compared to group C. The increase is statistically significant for animals from groups

AS1<sub>500</sub> and AS2<sub>500</sub>. As for the individual extracts a significant growth is observed for groups, SER<sub>500</sub>, VAL<sub>500</sub>, CRA<sub>500</sub>, MEL<sub>250</sub>, MEL<sub>500</sub>. All the other groups demonstrate decrease of this indicator compared to group C.

Table 4 compares the number of entries in the opened arms of Elevated plus maze Notk after Antistress I, Antistress II and the individual extracts contained in them are administrated on male Wistar rats for 14 days.

When compared to the control group – C, Notk increases in all groups, with the exception of HYP<sub>250</sub> in which the indicator decreases. In groups C<sub>0</sub>, AS1<sub>500</sub>, AS2<sub>500</sub>, VAL<sub>500</sub>, CRA<sub>100</sub>, CRA<sub>500</sub>, MEL<sub>250</sub> and MEL<sub>500</sub> the increase is statistically significant.

Table 5 compares the total number of entries in both arms of Elevated plus maze (Ntot) after Antistress I, Antistress II and the individual extracts contained in them are administrated on male Wistar rats for 14 days. Ntot is increased significantly for the groups treated with the combinations – AS1<sub>500</sub> and AS2<sub>500</sub> compared to the control group – C. The growth is more pronounced in AS2<sub>500</sub>. As for the individual extracts only groups CRA<sub>100</sub>, CRA<sub>500</sub> and MEL<sub>250</sub> increase significantly Ntot compared to C. For all other groups the observed increase in this indicator is statistically insignificant and for groups SER<sub>250</sub>, HYP<sub>250</sub>, MEL<sub>100</sub>, CRA<sub>250</sub> there is a decrease in Ntot compared to C. Table 6 compares the ratio of opened/total arm entries in Elevated plus maze (Notn) after Antistress I, Antistress II and the individual extracts contained in them are administrated on male Wistar rats for 14 days.

The evaluation of the indicator Notn demonstrates significant increase in two of the groups treated with the combinations - AS1<sub>500</sub> and AS2<sub>500</sub> compared to group C. As for the individual extracts, it could be observed statistically significant growth of the indicator for groups VAL<sub>500</sub>, CRA<sub>100</sub>, CRA<sub>500</sub>, MEL<sub>250</sub> and MEL<sub>500</sub> compared to group C. Moreover, Notn increases significantly for group C<sub>0</sub> compared to C.

Comparison of the results regarding the anxiolytic effect of the two combinations, administered at doses of 100, 250 and 500 mg/kg b.w.

Table 1: Design of the experiment in the study of acute toxicity in male Wistar rats.

Groups	Per os treatment with
1. Control	Distilled water 10ml/kg b.w.
2. Combination	Antistress I 5g/kg b.w.
3. Combination	Antistress I 10 g/kg b.w.
4. Combination	Antistress II 5 g/kg b.w.
5. Combination	Antistress II 10 g/kg b.w.
6. Individual extract	Serratula 5g/kg b.w.
7. Individual extract	Serratula 10 g/kg b.w.
8. Individual extract	Hypericum 5 g/kg b.w.
9. Individual extract	Hypericum 10 g/kg b.w.
10. Individual extract	Valeriana 5 g/kg b.w.
11. Individual extract	Valeriana 10 g/kg b.w.
12. Individual extract	Crataegus 5 g/kg b.w.
13. Individual extract	Crataegus 10 g/kg b.w.
14. Individual extract	Melissa 5g/kg b.w.
15. Individual extract	Melissa 10 g/kg b.w.

The comparison between Antistress I and Antistress II at doses of 100 and 250 mg/kg b.w. shows no significant difference in the values of the indicators for anxiolytic effect. However at a dose of 500 mg/kg b.w. there is a statistically significant increase of Totk, Notk and Ntot for group AS2<sub>500</sub> compared to group AS1<sub>500</sub>

Comparison of the results regarding the anxiolytic effect of Antistress I at doses of 100, 250 and 500 mg/kg b.w. and the individual extracts contained in this combination at the same doses.

The comparison of AS1<sub>100</sub> with SER<sub>100</sub>, MEL<sub>100</sub>, VAL<sub>100</sub> and CRA<sub>100</sub> doesn't demonstrate statistically significant difference between the indicators of anxiolytic effect. Similar results could be reported when comparing AS1<sub>250</sub> with SER<sub>250</sub>, MEL<sub>250</sub>, VAL<sub>250</sub> and CRA<sub>250</sub>. At a dose of 500 mg/kg b.w. there is a significant increase of Totk for groups CRA<sub>500</sub> and VAL<sub>500</sub> compared to group AS1<sub>500</sub>.

Comparison of the results regarding the anxiolytic effect of Antistress II at doses of 100, 250 and 500 mg/kg b.w. and the individual extracts contained in this combination at the same doses.

There is no statistically significant difference in the indicators of anxiolytic effect when comparing group AS2<sub>100</sub> with groups SER<sub>100</sub>, HYP<sub>100</sub> and VAL<sub>100</sub>. The comparison of AS2<sub>250</sub> with SER<sub>250</sub>, HYP<sub>250</sub> and VAL<sub>250</sub> shows similar results. Totk, Notk, Ntot and Notn decrease significantly for group SER<sub>500</sub> compared to group AS2<sub>500</sub>. The indicators -Totk, Notk and Ntot decrease for group HYP<sub>500</sub> compared to group AS2<sub>500</sub>. Only Notk and Ntot decrease significantly for group VAL<sub>500</sub> compared to group AS2<sub>500</sub>.

Comparison of the results regarding the anxiolytic effect between the different doses (100, 250 and 500) of the combination Antistress I and comparison of the results regarding the anxiolytic effect between the different doses (100, 250 and 500) of the combination Antistress II.

The comparison of AS1<sub>100</sub> and AS1<sub>250</sub> doesn't show statistically significant change of the indicators for anxiolytic effect. Similar results could be reported after comparing AS1<sub>250</sub> and AS1<sub>500</sub>. However a significant increase of Totk and Notk could be observed for AS1<sub>500</sub> after comparing this group with AS1<sub>100</sub>.

Table 2: Design of the experiment used for the evaluation of the anxiolytic effect in model of acute stress of the two combinations - Antistress I and Antistress II and the individual extracts included in them.

Group	Label	Description	Model of acute stress	Number of rats in each group
1	C	Distilled water per os 10 ml/kg b.w.	Yes	14
2	C <sub>0</sub>	Distilled water per os 10 ml/kg b.w	No	6
3	AS1 <sub>100</sub>	Antistress I per os 100 mg/kg b. w	Yes	6
4	AS1 <sub>250</sub>	Antistress I per os 250 mg/kg b. w	Yes	6
5	AS1 <sub>500</sub>	Antistress I per os 500 mg/kg b. w	Yes	8
6	AS2 <sub>100</sub>	Antistress II per os 100 mg/kg b. w	Yes	6
7	AS2 <sub>250</sub>	Antistress II per os 250 mg/kg b. w	Yes	6
8	AS2 <sub>500</sub>	Antistress II per os 500 mg/kg b. w	Yes	8
9	SER <sub>100</sub>	Serratula coronata per os 100 mg/ kg b. w	Yes	6
10	SER <sub>250</sub>	Serratula coronata per os 250 mg/ kg b. w	Yes	6
11	SER <sub>500</sub>	Serratula coronata per os 500 mg/ kg b. w	Yes	8
12	HYP <sub>100</sub>	Hypericum perforatum per os 100 mg/ kg b. w	Yes	6
13	HYP <sub>250</sub>	Hypericum perforatum per os 250 mg/ kg b. w	Yes	6
14	HYP <sub>500</sub>	Hypericum perforatum per os 500 mg/ kg b. w	Yes	8
15	VAL <sub>100</sub>	Valeriana officinalis per os 100 mg/ kg b. w	Yes	6
16	VAL <sub>250</sub>	Valeriana officinalis per os 250 mg/ kg b. w	Yes	6
17	VAL <sub>500</sub>	Valeriana officinalis per os 500 mg/ kg b. w	Yes	8
18	CRA <sub>100</sub>	Crataegus monogyna per os 100 mg/ kg b. w	Yes	6
19	CRA <sub>250</sub>	Crataegus monogyna per os 250 mg/ kg b. w	Yes	6
20	CRA <sub>500</sub>	Crataegus monogyna per os 500 mg/ kg b. w	Yes	8
21	MEL <sub>100</sub>	Melissa officinalis per os 100 mg/ kg b. w	Yes	6
22	MEL <sub>250</sub>	Melissa officinalis per os 250 mg/ kg b. w	Yes	6
23	MEL <sub>500</sub>	Melissa officinalis per os 500 mg/ kg b. w	Yes	8

Table 3: Time spent in the opened arms of Elevated plus maze measured in seconds - Totk (s) after Antistress I, Antistress II and the individual extracts contained in them are administrated on male Wistar rats for 14 days.

Groups	Number	Mean ± SEM	U	p
C	14	5,1 ± 2,0	10,5	0,007*
C <sub>0</sub>	6	36,2±11,6		
C	14	5,1 ± 2,0	38	0,724
AS1 <sub>100</sub>	6	2,7±1,5		
C	14	5,1 ± 2,0	39,5	0,825
AS1 <sub>250</sub>	6	6,5± 5,1		

C	14	5,1 ± 2,0	19	0,010*
AS1 <sub>500</sub>	8	14,7 ± 2,7		
C	14	5,1 ± 2,0	26	0,166
AS2 <sub>100</sub>	6	14,7 ± 6,8		
C	14	5,1 ± 2,0	41	0,930
AS2 <sub>250</sub>	6	3,2 ± 1,5		
C	14	5,1 ± 2,0	1	<0,001*
AS2 <sub>500</sub>	8	54,9 ± 8,4		
C	14	5,1 ± 2,0	39,5	0,826
SER <sub>100</sub>	6	11,5 ± 7,8		
C	14	5,1 ± 2,0	41,5	0,965
SER <sub>250</sub>	6	3,0 ± 1,0		
C	14	5,1 ± 2,0	24,5	0,026*
SER <sub>500</sub>	8	25,2 ± 7,6		
C	14	5,1 ± 2,0	38,5	0,757
HYP <sub>100</sub>	6	3,0 ± 1,6		
C	14	5,1 ± 2,0	24,5	0,103
HYP <sub>250</sub>	6	0,5 ± 0,5		
C	14	5,1 ± 2,0	37	0,173
HYP <sub>500</sub>	8	16,4 ± 6,8		
C	14	5,1 ± 2,0	39	0,786
VAL <sub>100</sub>	6	8,8 ± 7,2		
C	14	5,1 ± 2,0	37	0,652
VAL <sub>250</sub>	6	4,7 ± 3,6		
C	14	5,1 ± 2,0	11,5	0,002*
VAL <sub>500</sub>	8	36,6 ± 7,0		
C	14	5,1 ± 2,0	19,5	0,055
CRA <sub>100</sub>	6	18,3 ± 8,8		
C	14	5,1 ± 2,0	37,5	0,691
CRA <sub>250</sub>	6	3,0 ± 1,7		
C	14	5,1 ± 2,0	2	<0,001*
CRA <sub>500</sub>	8	45,0 ± 8,5		
C	14	5,1 ± 2,0	24,5	0,103
MEL <sub>100</sub>	6	0,5 ± 0,5		
C	14	5,1 ± 2,0	15	0,021*
MEL <sub>250</sub>	6	23,0 ± 7,0		
C	14	5,1 ± 2,0	15,5	0,010*
MEL <sub>500</sub>	8	27,6 ± 9,8		

\* The results are statistically significant.

The indicators for anxiolytic effect don't differ significantly after comparing AS2<sub>100</sub> and AS2<sub>250</sub>. There

is a significant increase of Totk, Notk, Ntot and Notn for AS2<sub>500</sub> compared to AS2<sub>250</sub>. The comparison of

AS2<sub>500</sub> with AS2<sub>100</sub> demonstrates significant increase of the indicators Totk and Notn.

### **DISCUSSION**

For the present experiments, we have selected the Elevated plus maze as an appropriate method to evaluate the anxiolytic effects of the combinations and the individual extracts. According to Pellow and File, in the assessment of behavioral responses of rodents, anxiety is studied most often by using the Elevated plus maze test, which is the main test for preclinical evaluation of drugs with anxiolytic effect<sup>10</sup>.

Table 4: Number of entries in the opened arms of Elevated plus maze (Notk) after Antistress I, Antistress II and the individual extracts contained in them are administrated on male Wistar rats for 14 days.

Groups	Number	Mean $\pm$ SEM	U	p
C	14	0,6 $\pm$ 0,2	18,5	0,038*
C <sub>0</sub>	6	2,3 $\pm$ 0,8		
C	14	0,6 $\pm$ 0,2	37,5	0,684
AS1 <sub>100</sub>	6	0,8 $\pm$ 0,4		
C	14	0,6 $\pm$ 0,2	39,5	0,819
AS1 <sub>250</sub>	6	1,2 $\pm$ 0,8		
C	14	0,6 $\pm$ 0,2	15,5	0,004*
AS1 <sub>500</sub>	8	2,2 $\pm$ 0,4		
C	14	0,6 $\pm$ 0,2	26	0,156
AS2 <sub>100</sub>	6	1,8 $\pm$ 0,7		
C	14	0,6 $\pm$ 0,2	40,5	0,891
AS2 <sub>250</sub>	6	0,7 $\pm$ 0,3		
C	14	0,6 $\pm$ 0,2	2	0,001*
AS2 <sub>500</sub>	6	4,7 $\pm$ 1,0		
C	14	0,6 $\pm$ 0,2	37	0,651
SER <sub>100</sub>	6	1,0 $\pm$ 0,5		
C	14	0,6 $\pm$ 0,2	34	0,466
SER <sub>250</sub>	6	0,8 $\pm$ 0,3		
C	14	0,6 $\pm$ 0,2	31,5	0,075
SER <sub>500</sub>	8	1,6 $\pm$ 0,5		
C	14	0,6 $\pm$ 0,2	40	0,855
HYP <sub>100</sub>	6	0,8 $\pm$ 0,5		
C	14	0,6 $\pm$ 0,2	30,5	0,276
HYP <sub>250</sub>	6	0,3 $\pm$ 0,3		
C	14	0,6 $\pm$ 0,2	40,5	0,254
HYP <sub>500</sub>	8	1,7 $\pm$ 0,8		
C	14	0,6 $\pm$ 0,2	41	0,927
VAL <sub>100</sub>	6	1,2 $\pm$ 0,8		
C	14	0,6 $\pm$ 0,2	38	0,711
VAL <sub>250</sub>	6	0,8 $\pm$ 0,6		
C	14	0,6 $\pm$ 0,2	20,5	0,024*
VAL <sub>500</sub>	8	2,0 $\pm$ 0,5		
C	14	0,6 $\pm$ 0,2	16,5	0,026*
CRA <sub>100</sub>	6	2,3 $\pm$ 0,8		
C	14	0,6 $\pm$ 0,2	40,5	0,891
CRA <sub>250</sub>	6	0,7 $\pm$ 0,3		
C	14	0,6 $\pm$ 0,2	8,5	0,001*
CRA <sub>500</sub>	8	4,5 $\pm$ 0,9		
C	14	0,6 $\pm$ 0,2	37,5	0,677
MEL <sub>100</sub>	6	0,7 $\pm$ 0,5		
C	14	0,6 $\pm$ 0,2	12,5	0,011*
MEL <sub>250</sub>	6	3,5 $\pm$ 1,0		

Referring to the available literature data we haven't found any information about combinations of plant extracts corresponding to the doses, the content and the ratios of the combinations included in our experiment. To explain the \* The results are statistically significant.

pharmacological effects of Antistress I and Antistress II, we have used information from the available literature

related to the chemical composition and the pharmacological effects of the individual extracts which are included in these combinations.

The group of rats treated with the combination Antistress I at a dose of 500 mg / kg b.w. demonstrates a significant increase in the indicators of anxiety. However, the individual plant extracts contained in Antistress I -

*Serratula coronata*, *Valeriana officinalis*, *Crataegus monogyna* and *Melissa officinalis*, when administered separately at a dose of 500 mg / kg b.w. have better anxiolytic effect compared to effects on the experimental animals treated with Antistress I. This is probably due to antagonistic interactions between them which occur after they are included in the combination.

Table 5: Total number of entries in both arms of Elevated plus maze (Ntot) after Antistress I, Antistress II and the individual extracts contained in them are administrated on male Wistar rats for 14 days.

Groups	Number	Mean $\pm$ SEM	U	p
C	14	2,3 $\pm$ 0,4	21,5	0,079
C <sub>0</sub>	6	4,7 $\pm$ 1,2		
C	14	2,3 $\pm$ 0,4	40,5	0,894
AS1 <sub>100</sub>	6	2,8 $\pm$ 1,1		
C	14	2,3 $\pm$ 0,4	29,5	0,276
AS1 <sub>250</sub>	6	3,8 $\pm$ 1,3		
C	14	2,3 $\pm$ 0,4	15,5	0,004*
AS1 <sub>500</sub>	8	5,0 $\pm$ 0,6		
C	14	2,3 $\pm$ 0,4	23,5	0,108
AS2 <sub>100</sub>	6	5,7 $\pm$ 2,0		
C	14	2,3 $\pm$ 0,4	29	0,258
AS2 <sub>250</sub>	6	3,3 $\pm$ 0,8		
C	14	2,3 $\pm$ 0,4	3	0,001*
AS2 <sub>500</sub>	6	8,5 $\pm$ 1,6		
C	14	2,3 $\pm$ 0,4	34	0,487
SER <sub>100</sub>	6	2,8 $\pm$ 0,7		
C	14	2,3 $\pm$ 0,4	41,5	0,965
SER <sub>250</sub>	6	2,0 $\pm$ 0,4		
C	14	2,3 $\pm$ 0,4	31	0,076
SER <sub>500</sub>	8	4,0 $\pm$ 0,8		
C	14	2,3 $\pm$ 0,4	41	0,930
HYP <sub>100</sub>	6	2,3 $\pm$ 0,7		
C	14	2,3 $\pm$ 0,4	27	0,160
HYP <sub>250</sub>	6	1,3 $\pm$ 0,3		
C	14	2,3 $\pm$ 0,4	45	0,425
HYP <sub>500</sub>	8	3,9 $\pm$ 1,3		
C	14	2,3 $\pm$ 0,4	35	0,543
VAL <sub>100</sub>	6	3,7 $\pm$ 1,6		
C	14	2,3 $\pm$ 0,4	37,5	0,683
VAL <sub>250</sub>	6	2,3 $\pm$ 1,0		
C	14	2,3 $\pm$ 0,4	25	0,062
VAL <sub>500</sub>	8	4,3 $\pm$ 0,9		
C	14	2,3 $\pm$ 0,4	14,5	0,019*
CRA <sub>100</sub>	6	5,7 $\pm$ 1,5		
C	14	2,3 $\pm$ 0,4	35	0,535
CRA <sub>250</sub>	6	1,7 $\pm$ 0,3		
C	14	2,3 $\pm$ 0,4	11,5	0,002*
CRA <sub>500</sub>	8	8,4 $\pm$ 1,5		
C	14	2,3 $\pm$ 0,4	33,5	0,441
MEL <sub>100</sub>	6	1,7 $\pm$ 0,5		
C	14	2,3 $\pm$ 0,4	13,5	0,015*
MEL <sub>250</sub>	6	8,8 $\pm$ 2,5		

The combination Antistress II administered at a dose of 500 mg / kg b.w shows significant increase in the main indicators of anxiety - Totk, Notk and Notn and this increase is greater compared to the increase of the groups \* The results are statistically significant.

Table 6: Ratio of opened/total arm entries in Elevated plus maze (Notn) after Antistress I, Antistress II and the individual extracts contained in them are administrated on male Wistar rats for 14 days.

Groups	Number	Mean $\pm$ SEM	U	p
C	14	0,18 $\pm$ 0,05	16	0,025*
C <sub>0</sub>	6	0,41 $\pm$ 0,09		
C	14	0,18 $\pm$ 0,05	41	0,929
AS1 <sub>100</sub>	6	0,21 $\pm$ 0,11		
C	14	0,18 $\pm$ 0,05	42	1,000
AS1 <sub>250</sub>	6	0,18 $\pm$ 0,09		
C	14	0,18 $\pm$ 0,05	20,5	0,012*
AS1 <sub>500</sub>	8	0,39 $\pm$ 0,06		
C	14	0,18 $\pm$ 0,05	36	0,601
AS2 <sub>100</sub>	6	0,24 $\pm$ 0,09		
C	14	0,18 $\pm$ 0,05	40	0,859
AS2 <sub>250</sub>	6	0,15 $\pm$ 0,07		
C	14	0,18 $\pm$ 0,05	4	0,001*
AS2 <sub>500</sub>	6	0,54 $\pm$ 0,03		
C	14	0,18 $\pm$ 0,05	37	0,658
SER <sub>100</sub>	6	0,22 $\pm$ 0,10		
C	14	0,18 $\pm$ 0,05	25	0,135
SER <sub>250</sub>	6	0,33 $\pm$ 0,10		
C	14	0,18 $\pm$ 0,05	34	0,118
SER <sub>500</sub>	8	0,33 $\pm$ 0,08		
C	14	0,18 $\pm$ 0,05	38,5	0,757
HYP <sub>100</sub>	6	0,22 $\pm$ 0,11		
C	14	0,18 $\pm$ 0,05	31,5	0,327
HYP <sub>250</sub>	6	0,11 $\pm$ 0,11		
C	14	0,18 $\pm$ 0,05	39,5	0,233
HYP <sub>500</sub>	8	0,30 $\pm$ 0,09		
C	14	0,18 $\pm$ 0,05	38	0,717
VAL <sub>100</sub>	6	0,14 $\pm$ 0,09		
C	14	0,18 $\pm$ 0,05	38,5	0,751
VAL <sub>250</sub>	6	0,15 $\pm$ 0,10		
C	14	0,18 $\pm$ 0,05	19,5	0,023*
VAL <sub>500</sub>	8	0,41 $\pm$ 0,08		
C	14	0,18 $\pm$ 0,05	22,5	0,095
CRA <sub>100</sub>	6	0,34 $\pm$ 0,08		
C	14	0,18 $\pm$ 0,05	33,5	0,451
CRA <sub>250</sub>	6	0,28 $\pm$ 0,13		
C	14	0,18 $\pm$ 0,05	10	0,001*
CRA <sub>500</sub>	8	0,52 $\pm$ 0,05		
C	14	0,18 $\pm$ 0,05	30,5	0,282
MEL <sub>100</sub>	6	0,08 $\pm$ 0,08		
C	14	0,18 $\pm$ 0,05	19,5	0,054
MEL <sub>250</sub>	6	0,35 $\pm$ 0,07		

treated with individual extracts of *Valeriana officinalis*, *Hypericum perforatum* and *Serratula coronata*. That could be explained with synergy between *Serratula coronata* and the others constituents in the combined extract. Moreover in the available literature is reported that hypericine contained in *Hypericum perforatum*, except its antidepressant properties, has also the ability to potentiate the anti-stress and adaptogenic effects of other plant extracts, when administered in combination with them. This explains its inclusion in the combined extract Antistress II<sup>11</sup>. Clinical study reports the beneficial effects in the treatment of anxiety-depressive disorders when *Valeriana officinalis* and *Hypericum perforatum* are applied in combination<sup>12</sup>. A preclinical study conducted by Patidar and Associates shows anxiolytic and sedative effects of combined extract and dry crude plant drug containing *Valeriana*, *Hypericum* and *Passiflora* at a dose of 400 mg / kg b.w. Besides the positive effects of the combination on anxiety it is also found that the dry crude drug demonstrates stronger sedative effect compared to the \* The results are statistically significant.

extract<sup>13</sup>.

The doses that we have selected for the experiments - 100, 250 and 500 mg / kg b.w. are similar to those chosen by other authors<sup>14</sup>. The results of our study using a model of acute stress show that dry extract from *Serratula coronata* exhibits anxiolytic effect by increasing Totk only at a dose of 500 mg / kg b.w. There is no dose-effect relation because the increase Totk and Notk is lowest at a dose of 250 mg / kg b.w. Another study gives information about the anxiolytic and adaptogenic effect of 20hydroxyecdysone, which is one of the main chemical compounds found in *Serratula coronata*<sup>15</sup>. There is no evidence in the available literature explaining the in vivo effects on anxiety of total *Serratula coronata* extract. Although the individual extract of *Serratula coronata* demonstrates anxiolytic effect in our experiments, its inclusion in the combinations Antistress I and Antistress II is 10 times less than the dose causing such an effect. This leads to the conclusion that *Serratula coronata* acts synergistically on the anxiolytic effects of the other ingredients in the combinations.

Regarding the individual *Valeriana officinalis* extract, it can be observed a dose-effect relation in the increase of Totk. This indicator has the smallest value at the lowest dose of 100 mg/kg b.w. and the greatest value in the highest dose of 500 mg/kg b.w. *Valeriana officinalis* contains triterpenes (valepotriates, valeronic acid, bornyl acetate, etc.). Valepotriates potentiate secretion and block reuptake of the main inhibitory CNS mediator - Gammaaminobutyric acid (GABA)<sup>16</sup>. Valeronic acid modulates GABA<sub>A</sub> receptors and also

supports the anxiolytic action<sup>17</sup>. In our study the individual *Valeriana officinalis* extract doesn't alter significantly the locomotor activity of rats. Our results correspond with these of Hattesoehl and co-authors, who investigate *Valeriana officinalis* extract, administrated orally. In their study, a dose of 1000 mg/kg b.w. doesn't exhibit sedative or miorelaxant effect<sup>18</sup>.

Locomotor activity in mouse doesn't decrease in the study of Hiller and co-authors<sup>19</sup>.

The extract of *Crataegus monogyna* shows anxiolytic effect at the highest dose by increasing significantly the indicators of anxiety. The anxiolytic effect is due to the flavonoid fraction in the extract (rutin, quercetin, hiperozid etc.). The observed increase in the overall locomotor activity expressed in Ntot demonstrates a lack of sedative effect. This doesn't correspond to the results from Can and co-authors, according to who the extract of seeds and pulp from *Crataegus monogyna* at a dose of 10 to 1000 mg / kg b.w. reduces the locomotor activity<sup>20</sup>. The differences in our results may be due to the fact that in our study, the extract of *Crataegus monogyna* is obtained from the leaves and flowers, but not from seeds and pulp thus has a different content of biologically active substances. In another study an ethanol extract of *Crataegus* shows anxiolytic effect in the elevated plus maze at doses of 300 and 600 mg. The mechanism of action is not fully understood, but it is probably due to influence upon GABA neurotransmission<sup>21</sup>. In our study, the lowest dose exhibits statistically significant effect only in Notk while increasing the locomotor activity. Furthermore, the individual extract from *Crataegus monogyna* doesn't show dose-effect relation.

In the current study it could be observed a dose-effect relation regarding Totk for the extract of *Melissa officinalis*. Our experiments also show significant increase of Totk and Notk at doses of 250 mg/kg b.w. and 500 mg/kg b.w. The anxiolytic effect of *Melissa officinalis* extract is probably due to the rosmarinic acid contained in the plant. It inhibits GABA-transaminase - the enzyme that is responsible for the degradation of GABA and thus potentiate its inhibitory effects in the CNS<sup>22</sup>. In a study of Taiwo and co-authors, *Melissa officinalis* at a doses of 100 and 300 mg / kg b.w., administered orally to rats for 15 days, exhibits a reduction of anxiety in the Elevated plus maze and the observed changes in Totk are also dosedependents<sup>23</sup>. Our current study shows significant increase of locomotor activity at doses of 100 and 500 mg/kg b.w., indicating a lack of sedative effect. These results regarding the anxiolytic effect of extract of *Melissa officinalis* are similar to results of other authors<sup>24</sup>.

Our current results allow us to assume direct relation between the anxiolytic effects of the combinations and the chemical composition of the individual extracts included in this study. The connection established by Leonard et al between anxiety and oxidative stress gave us reason to examine the antioxidant

activity of Antistress I and Antistress II in vitro by using three methods (ORAC, HORAC and electrochemical method) and in vivo by evaluating the effect of these combinations on anxiety after applying a model of acute stress on rats<sup>25</sup>. The more pronounced anxiolytic effects of the extracts of *Crataegus monogyna*, *Melissa officinalis* and *Valeriana officinalis* can be attributed to the higher percentage of polyphenolic compounds: flavonoids - rutin, quercetin, and hyperoside, vitexin; triterpenes - valepotriates, bornyl acetate, valerenic acid. The content of these compounds was determined by HPLC method developed at the Department of Chemistry and Biochemistry, Faculty of Pharmacy at the Medical University - Plovdiv. There is a correspondence between the results from the in vitro tests for antioxidant activity and the results from in vivo tests for anxiolytic activity obtained after the experiments with laboratory animals treated with Antistress I and Antistress II and the individual extracts which they contain. The results from chemical and experimental studies confirm the thesis of Halliwell for the necessity of both in vitro and in vivo pharmacodynamic interaction studies of the extracts<sup>26</sup>.

Both combinations - Antistress I and Antistress II are suitable for studying anxiety on a model of acute stress but only at the highest dose used in our experiment. The results about the anxiolytic effect of Antistress II on an acute stress model in rats give us the reason to conclude that this combination could be used for anxiety disorder combined with depression. Our results are confirmed with the data for antioxidant activity by using ORAC, HORAC and electrochemical method.

## REFERENCES

- Raskin I, Ribnický DM, Komarnýtsky S, Ilic N, Poulev A, Borisjuk N, et al. Plants and human health in the twenty-first century. *Trends Biotechnol.* 2002 Dec;20(12):522–31.
- Halberstein RA. Medicinal plants: historical and crosscultural usage patterns. *Ann Epidemiol.* 2005 Oct;15(9):686–99.
- Head KA, Kelly GS. Nutrients and botanicals for treatment of stress: adrenal fatigue, neurotransmitter imbalance, anxiety, and restless sleep. *Altern Med Rev.* 2009 Jun;14(2):114–40.
- Sakic B, Gauldie J, Denburg JA, Szechtman H. Behavioral effects of infection with IL-6 adenovector. *Brain Behav Immun.* 2001 Mar;15(1):25–42.
- Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. *Biol Psychiatry.* 2010 Mar;67(5):446–57.
- Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA.* 2001 Jul;286(3):327–34.
- Marin TJ, Chen E, Munch JA, Miller GE. Doubleexposure to acute stress and chronic family stress is associated with immune changes in children with asthma. *Psychosom Med.* 2009 May;71(4):378–84.
- Bricou O, Taieb O, Baubet T, Gal B, Guillevin L, Moro MR. Stress and coping strategies in systemic lupus erythematosus: a review. *Neuroimmunomodulation.* 2006;13(5-6):283–93.
- Himmerich H, Fischer J, Bauer K, Kirkby KC, Sack U, Krugel U. Stress-induced cytokine changes in rats. *Eur Cytokine Netw.* 2013 Jun;24(2):97–103.
- Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. *Pharmacol Biochem Behav.* 1986 Mar;24(3):525–9.
- Stansbury J, Saunders P, Winston D. Supporting Adrenal Function with Adaptogenic Herbs. *J Restor Med.* 2012;1(1):76–82.
- Müller D, Pfeil T, von den Driesch V. Treating depression comorbid with anxiety – results of an open, practice-oriented study with St John's wort WS® 5572 and valerian extract in high doses. *Phytomedicine.* 2003;10:25–30.
- Patidar P, Shaikh A, Dubey D, Dashora K. Herbal formulation for sedative and Antianxiety activity. 2012;5(11):5134–6.
- Vasil AS, Plotnikova AM, Aliev OI, Kalinkina GI, Angaskieva AS, Plotnikov MB. Hemorheological and Actoprotective Activity of *Serratula coronata* Extract in Exhausting Physical Exercise in Rats. 2007;143:14–7.
- Punegov V V., Sychov RL, Zainullin VG, Fedorov VN, Punegova N V. Extraction of ecdysterone-80 from *Serratula coronata* L. and assessment of its pharmacological action. Part I. Adaptogenic, gastroprotective, thermoprotective, and antihypoxic activity. *Pharm Chem J.* 2008;42(8):446–51.
- Lader M, Cardinali D, Pandi-Perumal S, editors. *Sleep and Sleep Disorders: A Neuropsychopharmacological Approach.* 1st ed. Springer US; 2006. XIII, 309.
- Yuan C-S, Mehendale S, Xiao Y, Aung HH, Xie J-T, Ang-Lee MK. The gamma-aminobutyric acid effects of valerian and valerenic acid on rat brainstem neuronal activity. *Anesth Analg.* 2004 Feb;98(2):353–8, table of contents.
- Hattesoehl M, Feistel B, Sievers H, Lehnfeld R, Hegger M, Winterhoff H. Extracts of *Valeriana officinalis* L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. *Phytomedicine.* 2008;15(1-2):2–15.
- Hiller K-O, Zetler G. Neuropharmacological Studies on Ethanol Extracts of *Valeriana officinalis* L.: Behavioural and Anticonvulsant Properties. *Phyther Res.* 1996 Mar 1;10(2):145–51.
- Can ÖD, Özkay ÜD, Öztürk N, Öztürk Y. Effects of hawthorn seed and pulp extracts on the central nervous system. *Pharm Biol.* 2010 Aug 1;48(8):924–31.
- Ankitkumar A, Ashok M, Jyothsna MV, Radhakrishna B. Evaluation of anxiolytic activity of aqueous and alcoholic extracts of leaves of *Crataegus oxyacantha* in mice. *Int J Pharm Biomed Sci.* 2011.
- Awad R, Muhammad A, Durst T, Trudeau VL, Arnason JT. Bioassay-guided fractionation of lemon balm

- (*Melissa officinalis* L.) using an in vitro measure of GABA transaminase activity. *Phyther Res.* 2009 Aug 1;23(8):1075–81.
23. Taiwo AE, Leite FB, Lucena GM, Barros M, Silveira D, Silva M V, et al. Anxiolytic and antidepressant-like effects of *Melissa officinalis* (lemon balm) extract in rats: Influence of administration and gender. *Indian J Pharmacol.* 2012 Jul 15;44(2):189–92.
24. Ibarra A, Feuillere N, Roller M, Lesburgere E, Beracochea D. Effects of chronic administration of *Melissa officinalis* L. extract on anxiety-like reactivity and on circadian and exploratory activities in mice. *Phytomedicine.* 2010;17(6):397–403.
25. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. *Neurosci Biobehav Rev.* 2012;36(2):764–85.
26. Halliwell B, Gutteridge J. *Free Radicals in Biology and Medicine.* IV. Oxford University Press; 2007. 888 p.